Catalog No.: PC-35267Not For Human Use, Lab Use Only.
VXc-486 (SPR719) is a novel inhibitor of gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro with MICs of 0.03-0.30 μg/ml and 0.08-5.48 μg/ml, respectively.
VXc-486 (SPR719) is a novel inhibitor of gyrase B, potently inhibits multiple drug-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis in vitro with MICs of 0.03-0.30 μg/ml and 0.08-5.48 μg/ml, respectively.
VXc-486 (SPR719) is active against drug-resistant isolates, has bactericidal activity, and kills intracellular and dormant M. tuberculosis bacteria in a low-oxygen environment.
VXc-486 (SPR719) inhibits the growth of multiple strains of Mycobacterium abscessus, Mycobacterium avium complex, and Mycobacterium kansasii (MICs=0.1-2.0 μg/ml), as well as several strains of Nocardia spp. (MICs=0.1-1.0 μg/ml).
VXc-486 (SPR719) reduces mycobacterial burdens in lungs of infected mice in vivo, sterilizes M. tuberculosis infection when combined with rifapentine-pyrazinamide and bedaquiline-pyrazinamide.
